Articles: human.
-
Chinese medical journal · Feb 2024
Randomized Controlled Trial Multicenter StudyTenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial.
A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA) has previously shown its preliminary efficacy in ST elevation myocardial infarction (STEMI) patients. This study was designed as a pivotal postmarketing trial to compare its efficacy and safety with rrecombinant human tissue-type plasminogen activator alteplase (rt-PA) in Chinese patients with STEMI. ⋯ rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery, a validated surrogate of clinical outcomes, among Chinese patients with acute STEMI.
-
Randomized Controlled Trial
The effect of EEG neurofeedback on lowering the stress reaction level depending on various stressors on the biochemical, muscular and psychomotor sphere: A preliminary randomized study.
The human body is exposed to stressors on a daily basis. Short-term exposure to a particular stressor can cause the release of inflammatory markers - including c-reactive protein (CRP). EEG neurofeedback is a noninvasive form of therapy that aims to improve brain function. Neurofeedback is a type of feedback based on brain activity. ⋯ This article shows the effect of EGG neurofeedback on reducing the negative effects of stress exposure in humans. The study showed that the level and a pattern of EEG neurofeedback influence and significance is different depending on the applied stressor. Furthermore, the level of EEG neurofeedback influence and significance in decreasing the stressor effect is different depending on the examined sphere.
-
Chinese medical journal · Jan 2024
Randomized Controlled Trial Multicenter StudyEfficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.
Atopic dermatitis (AD) affects approximately 10% of adults worldwide. CM310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 signaling. This trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe AD. ⋯ CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tolerated in adults with moderate-to-severe AD.
-
Randomized Controlled Trial
Clinical efficacy of rhGM-CSF gel and medical collagen sponge on deep second-degree burns of infants: A randomized clinical trial.
This study aimed to observe clinical efficacy of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) gel, medical collagen sponge and rhGM-CSF gel in combination with medical collagen sponge on deep second-degree burns of head, face or neck in infants. ⋯ rhGM-CSF gel in combination with medical collagen sponge is significantly effective in treating deep second-degree burns of head, face or neck in infants. This combination is beneficial for infection control, acceleration of scab dissolving and wound healing, and reduction of scar hyperplasia and pigmentation, which is worthy of clinical application and promotion.
-
Randomized Controlled Trial Multicenter Study
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes APRIL. ⋯ In patients with IgA nephropathy, 12 months of treatment with sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo. (Funded by Visterra; ENVISION ClinicalTrials.gov number, NCT04287985; EudraCT number, 2019-002531-29.).